Skip to main content

Market Overview

Piper Jaffray Discontinues Coverage on Alcon (ACL)


Piper Jaffray is out with its report today on Alcon (NYSE: ACL), discontinuing coverage on shares of ACL.

In a note to clients, Piper Jaffray writes, "On December 15, 2010, Alcon and Novartis agreed to a merger agreement whereby Novartis will acquire the 23% of Alcon shares it does not currently own and Alcon will subsequently become a division of Novartis. Novartis will pay Alcon shareholders compensation of $168/share, payable in shares of Novartis stock (maximum exchange ratio of 2.8x:1) and a contingent cash consideration to be paid out if the $168/share price is not reached using the maximum exchange ratio. With the belief that Novartis' acquisition of Alcon Inc. will close in the second quarter of 2011, we are discontinuing coverage of ACL shares."

Shares of ACL closed Wednesday at $164.28, down 0.27% from Tuesday's close.


Related Articles (ACL)

View Comments and Join the Discussion!

Posted-In: alcon Piper JaffrayAnalyst Color Analyst Ratings

Latest Ratings

CWBHFCantor FitzgeraldMaintains3.8
PRTSRoth CapitalMaintains30.0
MUXRoth CapitalMaintains2.0
BABAJP MorganInitiates Coverage On
CLARRoth CapitalMaintains24.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at